بررسی سطح بیان miR-34a و miR-375 ی در گردش در پلاسمای افراد مبتلا به سرطان معده و افراد سالم در استان گیلان
محورهای موضوعی :
مجله پلاسما و نشانگرهای زیستی
طلوع بابایی همتی
1
,
نجمه رنجی
2
,
فاطمه صفری
3
1 - گروه زیست شناسی، دانشکده علوم پایه، واحد رشت، دانشگاه آزاد اسلامی، رشت، ایران
2 - گروه زیست شناسی، دانشکده علوم پایه، واحد رشت، دانشگاه آزاد اسلامی، رشت، ایران
3 - گروه زیست شناسی، دانشکده علوم پایه، دانشگاه گیلان، رشت، ایران
تاریخ دریافت : 1401/03/25
تاریخ پذیرش : 1401/10/28
تاریخ انتشار : 1402/02/01
کلید واژه:
آنالیز راک,
سرطان معده,
miR-34a,
پلاسما,
miR-375,
چکیده مقاله :
چکیدهزمینه و هدف: سرطان معده ششمین بدخیمی شایع و چهارمین علت مرگ سرطانی در دنیا با نرخ بقای پایین است. تشخیص زود ممکن است بقای بیماران را افزایش و مرگ و میر را کاهش دهد. miRNA ها یک گروه از RNA های کوچک غیرکدکننده هستند که به عنوان تنظیم کننده منفی بیان ژنها در سطح پس از رونویسی عمل می کنند. هدف از این مطالعه ارزیابی بیان miR-34a و miR-375 در پلاسمای افراد مبتلا به سرطان معده در استان گیلان بود. مواد و روشها: در این مطالعه، 25 فرد مبتلا به سرطان معده و 25 فرد سالم در استان گیلان در طول 1397-1398 عضو شدند. بیان miR-34a و miR-375 در پلاسمای افراد مبتلا به سرطان معده و افراد سالم به روش Q-RT-PCR ارزیابی شد. ارتباط بین بیان و خصوصیات کلینیکوپاتولوژی بیماران بررسی شد. آنالیزمنحنی راک این miRNA ها انجام شد. نتایج: اختلاف معنی داری بین سطح پلاسمایی miR-34a و miR-375 در افراد مبتلا به سرطان معده در مقایسه با کنترل وجود نداشت. اختلاف معناداری بین سطح پلاسمایی miR-34aو miR-375 و نتایج کلینیکوپاتولوژی بیماران وجود نداشت. سطح زیر منحنی (AUC) آنالیز راک miR-34a 08/0 ±56/0 (P=0.42) بود. سطح زیر منحنی (AUC) آنالیز راک miR-375 08/0 ±62/0 (P=0.14) بود.نتیجه گیری: نتایج ما پیشنهاد می کند که miR-34a و miR-375 احتمالا بیومارکرهای مناسبی برای تشخیص سرطان معده در استان گیلان نباشند.
چکیده انگلیسی:
Introduction and Objective: Gastric cancer is the sixth most frequent malignancy and the fourth leading cause of cancer death in the world with poor survival rate. Early detection may increase patient’s survival and reduce mortality. miRNAs are small non-coding RNAs which function as negative regulators of genes expression in post-transcriptional level. The aim of this study was to evaluate the expression of miR-34a and miR-375 in the plasma of gastric cancer patients in Guilan province.Methods and materials: In this study, 25 gastric cancer patients and 25 healthy individuals in Guilan province during 2018-2019 were enrolled. The expression of miR-34a and miR-375 was evaluated in plasma of patients with Gastric cancer and healthy individuals by Q-RT-PCR method. The correlation between their expression and patient’s clinicopathological characteristics was also investigated. ROC curve analysis of the miRNAs was performed.Results: There was no significant difference in the plasma level of miR-34a and miR-375 in gastric cancer patients compared to control. There was no significant difference between the the plasma level of miR-34a and miR-375 and clinicopathological features of patients. Area under the curve (AUC) value of ROC analysis for miR-34a was 0.56±0.08 (P=0.42). Area under the curve (AUC) value of ROC analysis for miR-375 was 0.62±0.08 (P=0.14).Conclusion: Our results suggested that miR-34a and miR-375 probably don’t be appropriate biomarkers for diagnosis of gastric cancer in Guilan province.
منابع و مأخذ:
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2021;71(3):209-249.
2. Kalan Farmanfarma K, Mahdavifar N, Hassanipour S, Salehiniya H. Epidemiologic Study of Gastric Cancer in Iran: A Systematic Review. Clin Exp Gastroenterol. 2020;13:511-42.
3. Xing S, Tian Z, Zheng W, Yang W, Du N, Gu Y, et al. Hypoxia downregulated miR-4521 suppresses gastric carcinoma progression through regulation of IGF2 and FOXM1. Molecular Cancer. 2021;20(1):9.
4. Madhavan D, Cuk K, Burwinkel B, Yang R. Cancer diagnosis and prognosis decoded by blood-based circulating microRNA signatures. Front Genet. 2013;4:116-.
5. So JBY, Kapoor R, Zhu F, Koh C, Zhou L, Zou R, et al. Development and validation of a serum microRNA biomarker panel for detecting gastric cancer in a high-risk population. Gut. 2020:gutjnl-2020-322065.
6. Khakinezhad Tehrani F, Ranji N, Kouhkan F, Hosseinzadeh S. Apoptosis induction and proliferation inhibition by silibinin encapsulated in nanoparticles in MIA PaCa-2 cancer cells and deregulation of some miRNAs. Iran J Basic Med Sci. 2020;23(4):469-82.
7. O'Brien J, Hayder H, Zayed Y, Peng C. Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation. Front Endocrinol (Lausanne). 2018;9:402-.
8. Turchinovich A, Burwinkel B. Distinct AGO1 and AGO2 associated miRNA profiles in human cells and blood plasma. RNA Biol. 2012;9(8):1066-7
9. Sohel MH. Extracellular/Circulating MicroRNAs: Release Mechanisms, Functions and Challenges. Achievements in the Life Sciences. 2016;10(2):175-86.
10. Xiong S, Hu M, Li C, Zhou X, Chen H. Role of miR‑34 in gastric cancer: From bench to bedside (Review). Oncol Rep. 2019;42(5):1635-46.
11. Ni H, Qin H, Sun C, Liu Y, Ruan G, Guo Q, et al. MiR-375 reduces the stemness of gastric cancer cells through triggering ferroptosis. Stem Cell Res Ther. 2021;12(1):325.
12. Ding L, Xu Y, Zhang W, Deng Y, Si M, Du Y, et al. MiR-375 frequently downregulated in gastric cancer inhibits cell proliferation by targeting JAK2. Cell Res. 2010;20(7):784-93.
13. Song J, Bai Z, Han W, Zhang J, Meng H, Bi J, et al. Identification of suitable reference genes for qPCR analysis of serum microRNA in gastric cancer patients. Dig Dis Sci. 2012;57(4):897-904.
14. Li Z, Liu ZM, Xu BH. A meta-analysis of the effect of microRNA-34a on the progression and prognosis of gastric cancer. European review for medical and pharmacological sciences. 2018;22(23):8281-7.
15. Imani S, Zhang X, Hosseinifard H, Fu S, Fu J. The diagnostic role of microRNA-34a in breast cancer: a systematic review and meta-analysis. Oncotarget. 2017;8(14):23177-87.
16. Liu R, Zhang C, Hu Z, Li G, Wang C, Yang C, et al. A five-microRNA signature identified from genome-wide serum microRNA expression profiling serves as a fingerprint for gastric cancer diagnosis. European Journal of Cancer. 2011;47(5):784-91.
17. Ranji N, Sadeghizadeh M, Shokrgozar MA, Bakhshandeh B, Karimipour M, Amanzadeh A, et al. MiR-17-92 cluster: an apoptosis inducer or proliferation enhancer. Molecular and cellular biochemistry. 2013;380(1-2):229-38.
18. Jafari N, Abediankenari S, Hosseini-Khah Z, Valizadeh SM, Torabizadeh Z, Zaboli E, et al. Expression patterns of seven key genes, including β-catenin, Notch1, GATA6, CDX2, miR-34a, miR-181a and miR-93 in gastric cancer. Scientific Reports. 2020;10(1):12342.
19. Kalfert D, Ludvikova M, Pesta M, Ludvik J, Dostalova L, Kholová I. Multifunctional Roles of miR-34a in Cancer: A Review with the Emphasis on Head and Neck Squamous Cell Carcinoma and Thyroid Cancer with Clinical Implications. Diagnostics (Basel). 2020;10(8).
20. Zhang X, Yan Z, Zhang J, Gong L, Li W, Cui J, et al. Combination of hsa-miR-375 and hsa-miR-142-5p as a predictor for recurrence risk in gastric cancer patients following surgical resection. Annals of oncology : official journal of the European Society for Medical Oncology. 2011;22(10):2257-66.
21. Lee SW, Park KC, Kim JG, Moon SJ, Kang SB, Lee DS, et al. Dysregulation of MicroRNA-196b-5p and MicroRNA-375 in Gastric Cancer. J Gastric Cancer. 2016;16(4):221-9.
22. Juzenas S, Salteniene V, Kupcinskas J, Link A, Kiudelis G, Jonaitis L, et al. Analysis of Deregulated microRNAs and Their Target Genes in Gastric Cancer. PLoS One. 2015;10(7):e0132327.
_||_
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2021;71(3):209-249.
2. Kalan Farmanfarma K, Mahdavifar N, Hassanipour S, Salehiniya H. Epidemiologic Study of Gastric Cancer in Iran: A Systematic Review. Clin Exp Gastroenterol. 2020;13:511-42.
3. Xing S, Tian Z, Zheng W, Yang W, Du N, Gu Y, et al. Hypoxia downregulated miR-4521 suppresses gastric carcinoma progression through regulation of IGF2 and FOXM1. Molecular Cancer. 2021;20(1):9.
4. Madhavan D, Cuk K, Burwinkel B, Yang R. Cancer diagnosis and prognosis decoded by blood-based circulating microRNA signatures. Front Genet. 2013;4:116-.
5. So JBY, Kapoor R, Zhu F, Koh C, Zhou L, Zou R, et al. Development and validation of a serum microRNA biomarker panel for detecting gastric cancer in a high-risk population. Gut. 2020:gutjnl-2020-322065.
6. Khakinezhad Tehrani F, Ranji N, Kouhkan F, Hosseinzadeh S. Apoptosis induction and proliferation inhibition by silibinin encapsulated in nanoparticles in MIA PaCa-2 cancer cells and deregulation of some miRNAs. Iran J Basic Med Sci. 2020;23(4):469-82.
7. O'Brien J, Hayder H, Zayed Y, Peng C. Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation. Front Endocrinol (Lausanne). 2018;9:402-.
8. Turchinovich A, Burwinkel B. Distinct AGO1 and AGO2 associated miRNA profiles in human cells and blood plasma. RNA Biol. 2012;9(8):1066-7
9. Sohel MH. Extracellular/Circulating MicroRNAs: Release Mechanisms, Functions and Challenges. Achievements in the Life Sciences. 2016;10(2):175-86.
10. Xiong S, Hu M, Li C, Zhou X, Chen H. Role of miR‑34 in gastric cancer: From bench to bedside (Review). Oncol Rep. 2019;42(5):1635-46.
11. Ni H, Qin H, Sun C, Liu Y, Ruan G, Guo Q, et al. MiR-375 reduces the stemness of gastric cancer cells through triggering ferroptosis. Stem Cell Res Ther. 2021;12(1):325.
12. Ding L, Xu Y, Zhang W, Deng Y, Si M, Du Y, et al. MiR-375 frequently downregulated in gastric cancer inhibits cell proliferation by targeting JAK2. Cell Res. 2010;20(7):784-93.
13. Song J, Bai Z, Han W, Zhang J, Meng H, Bi J, et al. Identification of suitable reference genes for qPCR analysis of serum microRNA in gastric cancer patients. Dig Dis Sci. 2012;57(4):897-904.
14. Li Z, Liu ZM, Xu BH. A meta-analysis of the effect of microRNA-34a on the progression and prognosis of gastric cancer. European review for medical and pharmacological sciences. 2018;22(23):8281-7.
15. Imani S, Zhang X, Hosseinifard H, Fu S, Fu J. The diagnostic role of microRNA-34a in breast cancer: a systematic review and meta-analysis. Oncotarget. 2017;8(14):23177-87.
16. Liu R, Zhang C, Hu Z, Li G, Wang C, Yang C, et al. A five-microRNA signature identified from genome-wide serum microRNA expression profiling serves as a fingerprint for gastric cancer diagnosis. European Journal of Cancer. 2011;47(5):784-91.
17. Ranji N, Sadeghizadeh M, Shokrgozar MA, Bakhshandeh B, Karimipour M, Amanzadeh A, et al. MiR-17-92 cluster: an apoptosis inducer or proliferation enhancer. Molecular and cellular biochemistry. 2013;380(1-2):229-38.
18. Jafari N, Abediankenari S, Hosseini-Khah Z, Valizadeh SM, Torabizadeh Z, Zaboli E, et al. Expression patterns of seven key genes, including β-catenin, Notch1, GATA6, CDX2, miR-34a, miR-181a and miR-93 in gastric cancer. Scientific Reports. 2020;10(1):12342.
19. Kalfert D, Ludvikova M, Pesta M, Ludvik J, Dostalova L, Kholová I. Multifunctional Roles of miR-34a in Cancer: A Review with the Emphasis on Head and Neck Squamous Cell Carcinoma and Thyroid Cancer with Clinical Implications. Diagnostics (Basel). 2020;10(8).
20. Zhang X, Yan Z, Zhang J, Gong L, Li W, Cui J, et al. Combination of hsa-miR-375 and hsa-miR-142-5p as a predictor for recurrence risk in gastric cancer patients following surgical resection. Annals of oncology : official journal of the European Society for Medical Oncology. 2011;22(10):2257-66.
21. Lee SW, Park KC, Kim JG, Moon SJ, Kang SB, Lee DS, et al. Dysregulation of MicroRNA-196b-5p and MicroRNA-375 in Gastric Cancer. J Gastric Cancer. 2016;16(4):221-9.
22. Juzenas S, Salteniene V, Kupcinskas J, Link A, Kiudelis G, Jonaitis L, et al. Analysis of Deregulated microRNAs and Their Target Genes in Gastric Cancer. PLoS One. 2015;10(7):e0132327.
